Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05279131 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
A Phase 3 study, sponsored by Almirall, S.A..
- Completed
- Registry status
- Phase 3
- Development phase
- 105
- Enrollment target
NCT05279131 is a Phase 3 study that has completed, run by Almirall, S.A.. The registered enrollment target is 105 participants.
The verdict
NCT05279131, a Phase 3 study, has completed, sponsored by Almirall, S.A..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 105 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety, tolerability and treatment effect of tirbanibulin ointment 1% when applied to a field of approximately 100 cm\^2 on the face or balding scalp.
Interventions
- DRUG Tirbanibulin ointment 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2022-06-28 |
| Est. Completion | 2022-12-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05279131
The ClinicalTrials.gov registry entry for NCT05279131 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Almirall, S.A., which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tirbanibulin ointment 1% is the first listed.
NCT05279131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05279131 about?
NCT05279131 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis". The purpose of the study is to evaluate the safety, tolerability and treatment effect of tirbanibulin ointment 1% when applied to a field of approximately 100 cm\^2 on the face or balding scalp.
What is the current status of trial NCT05279131?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 105 participants. The study started on 2022-06-28. Estimated completion is 2022-12-28.
What interventions are being tested in trial NCT05279131?
The interventions under investigation include: Tirbanibulin ointment 1% (DRUG).
Who is sponsoring clinical trial NCT05279131?
This trial is sponsored by Almirall, S.A., which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.